Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: Data from the AutoImmunity and Rituximab registry

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Salmon, J H ^a   Cacoub, P ^b   Combe, B ^c   Sibilia, J ^d   Pallot Prades, B ^e   Fain, O ^f   Cantagrel, A ^g   Dougados, M ^h   Andres, E ⁱ   Meyer, O ^j   Carli, P ^k   Pertuiset, E ^l   Pane, I ^m   Maurier, F ⁿ   Ravaud, P ^m   Mariette, X ^o   Gottenberg, J E ^d  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b CNRS   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f HÔPITAL JEAN VERDIER   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j BICHAT HOSPITAL   (France)

^k Service de Médecine Hyperbare et Expertise Plongée Military Teaching Hospital   (France)

^l CENTRE HOSPITALIER RENÉ DUBOS   (France)

^m PARIS DESCARTES UNIVERSITY   (France)

ⁿ CHR Metz   (France)

^o UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193310     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2014-000034     Document Type: Article

References (21)

1. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010;47:180-6.
2. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
3. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007;92:20-3.
4. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-4.
5. Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximabtreated lymphoma patients: report of two cases. Leuk Res 2002;26:597-600.
6. Papadaki T, Stamatopoulos K, Anagnostopoulos A, et al. Rituximab-associated immune myelopathy. Blood 2003;102:1557-8.
7. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999;10:463-71.
8. Weng WK, Negrin RS, Lavori P, et al. Immunoglobulin G Fc receptor FcgammaRIIIa 158V/F polymorphism correlates with rituximabinduced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010;28:279-84.
9. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol 2010;85:810-12.
10. Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011;63:2209-14.
11. Goh MS, McCormack C, Dinh HV, et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007;156:990-6.
12. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007;157:1271-3.
13. Besada E, Koldingsnes W, Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 2012;105:545-50.
14. Besada E. Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al. Arthritis Rheum 2012;64:596-7.
15. Abdulkader R, Dharmapalaiah C, Rose G, et al. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 2014;41:858-61.
16. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011;50:222-9.
17. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
18. Cattaneo C, Spedini P, Casari S et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013-17.
19. Pfreundschuh M, Muller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2014;123:640-6.
20. Van Vollenhoven RF, Emery P, Bingham CO, III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
21. Pham T, Fautrel B, Gottenberg JE, et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008;75(Suppl 1):S1-99.